ArticleCureus2025
Hematological Indices and Abnormalities in Chronic Kidney Disease and Their Associations With Disease Severity.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectiveChronic kidney disease (CKD) is frequently complicated by hematological abnormalities, including anemia, thrombocytopenia, and leukocyte disorders, which significantly impact morbidity and survival. This study aimed to evaluate hematological indices and abnormalities in patients with CKD and determine their associations with disease severity across stages 3-5.
methodsThis cross-sectional observational study was carried out in the Department of Nephrology, Lahore General Hospital, Pakistan, between August 2023 and February 2024, following Institutional Review Board approval. A total of 412 patients aged 18-70 years with CKD stages 3-5, defined by Kidney Disease: Improving Global Outcomes (KDIGO) criteria, were recruited using non-probability consecutive sampling after obtaining written informed consent. Patients with known hematological disorders, acute infections, malignancy, chronic hepatitis B or C, HIV, recent blood transfusion, use of erythropoiesis-stimulating agents, or pregnancy were excluded. Venous blood samples (10 mL) were collected under aseptic precautions and analyzed for hematological indices using the Sysmex KX-2 analyzer (Kobe, Japan). Biochemical parameters were measured on Cobas Integra 400 Plus (Roche Diagnostics, Germany).
resultsA total of 412 patients were evaluated, with a mean age of 44.26 ± 14.05 years; 181 (43.9%) were aged 18-45 years, and 231 (56.1%) were 46-70 years. Men comprised 266 (64.6%) and women 146 (35.4%). The mean disease duration was 4.93 ± 2.61 years, with 247 (60%) reporting <5 years. Diabetes mellitus (40%) and hypertension (31.3%) were the leading etiologies. CKD stages included 100 (24.3%) in stage 3, 169 (41%) in stage 4, and 143 (34.7%) in stage 5. Hemoglobin (Hb) declined from 12.65 ± 1.05 g/dL (stage 3) to 9.98 ± 1.97 g/dL (stage 5, p < 0.001). Hematocrit (Hct) decreased from 35.61 ± 4.33% to 29.20 ± 5.45%, red blood cell (RBC) count from 4.04 ± 0.74 × 10¹²/L to 3.38 ± 0.50 × 10¹²/L, and platelet (PLT) count from 272.15 ± 116.68 × 10⁹/L to 197.82 ± 130.32 × 10⁹/L. Red cell distribution width (RDW) increased from 13.58 ± 1.37% to 15.79 ± 1.50% (p < 0.001). Anemia was present in 38%, 68%, and 92.3% of stages 3, 4, and 5, respectively; thrombocytopenia (14%-34.3%), leukopenia (11%-25.2%), and leukocytosis (7%-22.4%) also increased significantly with disease severity.
conclusionHematological indices deteriorate with advancing CKD, with anemia, thrombocytopenia, and leukocyte abnormalities showing strong associations with disease severity. Routine hematological monitoring is essential for early detection and management of these complications to mitigate disease-related morbidity and improve patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.